Skip to main content

Errata - English

PDF CSV April 4, 2023 through April 4, 2025 All Errata for USP–NF How to use
Enter the title of the monograph
Monograph Title Section Source Publication Page Number Errata Official Date Target Errata Print Publication Target Online Fix Publication Description
BUTORPHANOL TARTRATE NASAL SOLUTION IMPURITIES/Organic Impurities First Supplement to USP37–NF32 6596 1-Apr-2015 USP39–NF34 USP39–NF34 Row 3 of Column 1 of Table 1: Change
6-Butorphanol
to:
Δ6-Butorphanol
CISATRACURIUM BESYLATE INJECTION ASSAY/Procedure USP38–NF33 2830 1-Apr-2015 USP39–NF34 USP39–NF34 Line 11 of Analysis: Change
CS = concentration of USP Cisatracurium Besylate RS in the Standard solution
to:
CS = concentration of USP Cisatracurium Besylate RS in the Standard solution (mg/mL)
QUETIAPINE TABLETS PERFORMANCE TESTS/Dissolution <711>/Test 3 USP38–NF33 5104 1-Apr-2015 USP39–NF34 USP39–NF34 Line 7 of Instrumental conditions: Change
10 0mg,
to:
100 mg,
AND
Line 5 of Tolerances: Change
For Tablets labeled to contain 100 mg, 200 mg, 300 mg, or 400 mg:
to:
For Tablets labeled to contain 50 mg, 100 mg, 200 mg, 300 mg, or 400 mg:
MESALAMINE RECTAL SUSPENSION OTHER COMPONENTS/Content of Sodium Benzoate (if present) USP38–NF33 4270 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 5 of Analysis: Change
Result = (rU/rS) × CS × (10/W) × 100
to:
Result = (rU/rS) × CS × (10/W)
CHLORAMPHENICOL SODIUM SUCCINATE Limit of free chloramphenicol USP37–NF32 2285 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 10 of Chromatographic system: Change
Chromatograph the Standard solution, and record the peak areas as directed for Procedure: the relative standard deviation for replicate injections is not less than 2.0%.
to:
Chromatograph the Standard solution, and… Read More
CIPROFLOXACIN EXTENDED-RELEASE TABLETS PERFORMANCE TESTS/Dissolution <711> Revision Bulletin (Official October 01, 2014) Online 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 13 of Analysis in Test 1: Change
Mr2 = molecular weight of ciprofloxacin hydrochloride, 367.81
to:
Mr2 = molecular weight of anhydrous ciprofloxacin hydrochloride, 367.81
AND
Line 12 of Analysis in Test… Read More
METHOTREXATE IMPURITIES/Organic Impurities/Procedure 1: Related Compounds USP37–NF32 3762 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 1 of Standard solution A: Change
0.1 μg/mL of USP Methotrexate RS in Solution A, from the Standard stock solution
to:
0.1 µg/mL of USP Methotrexate RS in Solution A, from Standard stock solution A
TERAZOSIN TABLETS PERFORMANCE TESTS/Dissolution <711> USP37–NF32 4874 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 10 of Analysis: Change
Mr2 = molecular weight of terazosin hydrochloride dihydrate, 459.92
to:
Mr2 = molecular weight of terazosin hydrochloride, 423.89
EXTENDED PHENYTOIN SODIUM CAPSULES IDENTIFICATION/A. Infrared Absorption—General <197> First Supplement to USP37–NF32 6681 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 1 of Sample: Change
6 mg/mL of phenytoin sodium in water from a suitable number of Capsules prepared as follows. Nominally transfer 300 mg of the powder into 50 mL of water in a separator.
to:
300 mg of phenytoin sodium from the contents of Capsules in 50 mL of water in a… Read More
BUTABARBITAL SODIUM ORAL SOLUTION ASSAY/Procedure USP38–NF33 2500 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 17 of Analysis: Change
CU = nominal concentration of butabarbital sodium in the Sample solution (µg/mL)
to:
CU = nominal concentration of butabarbital sodium in the Sample solution (mg/mL)
CITRIC ACID, MAGNESIUM OXIDE, AND SODIUM CARBONATE IRRIGATION ASSAY/Citric Acid USP38–NF33 2844 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 16 of Analysis: Change
CU = nominal concentration of citric acid monohydrate in the Assay preparation for citric acid/citrate assay (units/mL)
to:
CU = nominal concentration of citric acid monohydrate in the Assay… Read More
AZITHROMYCIN IMPURITIES/Organic Impurities/Procedure 1 USP37–NF32 1886 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 6 of Analysis: Change
Calculate the percentages of desosaminylazithromycin and N-demethylazithromycin in the portion of Azithromycin taken:
to:
Calculate the percentages of desosaminylazithromycin, N-demethylazithromycin, and azaerythromycin A in the portion of… Read More
VALSARTAN AND HYDROCHLOROTHIAZIDE TABLETS ADDITIONAL REQUIREMENTS/USP Reference Standards <11> Revision Bulletin (Official April 01, 2014) Online 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 2 of USP Valsartan Related Compound B RS: Change
(S-N-Butyryl-N-([2′-(1H-tetrazole-5-yl)biphen-4-yl]methyl)-valine.
to:
N-Butyryl-N-{[2′-(1H-tetrazole-5-yl)biphenyl-4-yl]methyl}-L-valine.
HYDROGEN PEROXIDE CONCENTRATE ASSAY/Procedure USP37–NF32 3272 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 1 of Sample solution: Change
1 mL of Concentrate, diluted to 100 mL
to:
Weigh about 1 mL of Concentrate in a 100-mL volumetric flask, and dilute with water to volume.
POTASSIUM BITARTRATE IDENTIFICATION USP37–NF32 4346 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Change
C. Identification Tests—General, Tartrate <191>
to:
C. Identification Tests—General, Tartrate <191>: Meets the requirements
AND
Delete subsections:
Sample solution: 1 in 10 solution
Acceptance criteria: Meets the requirements
ZIPRASIDONE HYDROCHLORIDE IMPURITIES/Limit of Tetrahydrofuran USP37–NF32 5219 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 1 of Standard solution: Change
0.05 mg/mL of USP Ziprasidone Hydrochloride RS in dimethyl sulfoxide
to:
0.05 mg/mL of tetrahydrofuran in dimethyl sulfoxide
AMIODARONE HYDROCHLORIDE ORGANIC IMPURITIES/Procedure 1/Chromatographic system USP38–NF33 2198 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 1 of Adsorbent: Change
0.5-mm layer of chromatographic silica gel and fluorescent indicator with maximum absorbance at 254 nm
to:
Suitable layer of chromatographic silica gel and fluorescent indicator with maximum absorbance at 254 nm
CAFFEINE CITRATE ORAL SOLUTION ASSAY/Procedure USP38–NF33 2521 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 5 of Analysis: Change
Result = (rU/rS) × CS × (Mr1/Mr2) × 100
to:
Result = (rU/rS) × C Read More
PAROXETINE HYDROCHLORIDE IMPURITIES/Limit of 1-Methyl-4-(p-fluorophenyl)-1,2,3,6-tetrahydropyridine USP38–NF33 4765 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 1 of Standard solution: Change
42 mg/mL
to:
42 ng/mL
ESTRADIOL VAGINAL INSERTS PERFORMANCE TESTS/Dissolution <711> USP37–NF32 2866 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 3 of Analysis: Change
Calculate the amount of estradiol (C18H24O2) dissolved:
to:
Record the chromatograms, and measure the responses for the estradiol peak. Construct a calibration curve by plotting the peak response versus concentration of… Read More
CIPROFLOXACIN EXTENDED-RELEASE TABLETS IMPURITIES/Organic Impurities Revision Bulletin (Official October 01, 2014) Online 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 16 of Analysis: Change
Mr2 = molecular weight of ciprofloxacin hydrochloride, 367.81
to:
Mr2 = molecular weight of anhydrous ciprofloxacin hydrochloride, 367.81
AND
Line 14 of the second Calculate statement in Analysis… Read More
PACLITAXEL Related compounds/Test 2 (for Material Labeled as Produced by a Semisynthetic Process) USP37–NF32 4163 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 6 after table in Chromatographic system: Change
the relative standard deviation for replicate injections is not more than 2.0%.
to:
the relative standard deviation for replicate injections is not more than 2.0% for the paclitaxel peak.
TETRACAINE OINTMENT Assay USP37–NF32 4891 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 7 of Procedure: Change
(264.37/300.83)(C)(AU / AS)
to:
(264.36/300.82)(C)(AU / AS)
GLYCERYL BEHENATE ASSAY/Procedure/Chromatographic system Second Supplement to USP37–NF32 7075 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 1 of Column: Change
7.0-mm × 60-cm; 5-µm packing L21
[Note—Two 7.0-mm × 30-cm L21 columns
to:
7.5-mm × 60-cm; 5-µm 100-Å packing L21
[Note—Two 7.5-mm × 30-cm L21 columns
BUTABARBITAL SODIUM TABLETS PERFORMANCE TESTS/Uniformity of Dosage Units <905>/Procedure for content uniformity USP38–NF33 2501 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 18 of Analysis: Change
CU = nominal concentration of butabarbital sodium in the Sample solution
to:
CU = nominal concentration of butabarbital sodium in the Sample solution (mg/mL)
ESCITALOPRAM TABLETS PERFORMANCE TESTS/Dissolution <711>/Test 2 USP38–NF33 3364 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 13 of Analysis: Change
Mr2 = molecular weight of escitalopram oxalate, 405.30
to:
Mr2 = molecular weight of escitalopram oxalate, 414.43
AZITHROMYCIN SPECIFIC TESTS/pH <791> USP37–NF32 1886 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 1 of Sample solution: Change
2 mg/mL from the Sample stock solution in a mixture of methanol and water (1:1)
to:
2 mg/mL obtained by mixing equal volumes of Sample stock solution and water
CIPROFLOXACIN EXTENDED-RELEASE TABLETS ASSAY/Procedure Revision Bulletin (Official October 01, 2014) Online 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 17 of Analysis: Change
Mr2 = molecular weight of ciprofloxacin hydrochloride, 367.81
to:
Mr2 = molecular weight of anhydrous ciprofloxacin hydrochloride, 367.81
HYOSCYAMINE SULFATE USP Reference standards <11> USP37–NF32 3293 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 2 of USP Hyoscyamine Related Compound A RS: Change
(1R,3R,5S)-8-azabicyclo[3.2.1]oct-3-yl(2S)-3-hydroxy-2-phenylpropanoate.
to:
(1R,3r,5S)-8-Azabicyclo[3.2.1]oct-3-yl(2S)-3-hydroxy-2-phenylpropanoate sulfate (2:1).
POTASSIUM SODIUM TARTRATE Identification/C: USP37–NF32 4369 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Change
A solution (1 in 10) responds to the tests for Tartrate <191>.
to:
Responds to the tests for Tartrate <191>.
RED CLOVER TABLETS SPECIFIC TESTS/Microbial Enumeration Tests <2021> USP37–NF32 5526 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 4: Change
NLT 103 cfu/g.
to:
NMT 103 cfu/g.
ATROPINE SULFATE ADDITIONAL REQUIREMENTS/USP Reference Standards <11> USP38–NF33 2325 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 2 of USP Hyoscyamine Related Compound A RS: Change
Norhyoscyamine sulfate; (1R,3r,5S)-8-azabicyclo [3.2.1]oct-3-yl(2S)-3-hydroxy-2-phenylpropanoate.C16H21NO3 275.34
to:
Norhyoscyamine sulfate; (1R,3r,5… Read More
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE TABLETS ASSAY/Procedure USP38–NF33 2752 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 1 of Buffer: Change
0.20 sodium hydroxide
to:
0.20 N sodium hydroxide
PAROXETINE HYDROCHLORIDE ADDITIONAL REQUIREMENTS/USP Reference Standards <11> USP38–NF33 4765 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Lines 4 and 7 of USP Paroxetine System Suitability Mixture A RS: Change
hydrochloride (3 S-trans)
to:
hydrochloride (3S-trans)
GADOVERSETAMIDE INJECTION Relaxivity <761> USP37–NF32 3121 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 1 of Apparatus: Change
Use a mini-NMR spectrometer with suitable sensitivity (see Apparatus under Nuclear Magnetic Resonance <761>).
to:
Use an NMR spectrometer with suitable sensitivity.
BUPROPION HYDROCHLORIDE EXTENDED-RELEASE TABLETS IMPURITIES/Organic Impurities Revision Bulletin (Official October 01, 2014) Online 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Row 4 of Column 1 of Table 16: Change
R,S,S,-Thiomorpholine derivativec
to:
S,R,R,-Thiomorpholine derivativec
PANCURONIUM BROMIDE ASSAY/Procedure/Chromatographic system USP37–NF32 4176 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 1 of Column: Change
4.6-mm × 250-cm; 5-µm packing L1
to:
4.6-mm × 25-cm; 5-µm packing L1
VALSARTAN TABLETS PERFORMANCE TESTS/Dissolution <711> USP37–NF32 5116 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 1 of Medium: Change
pH 6.8 phosphate buffer; 1000 mL, degassed
to:
pH 6.8 phosphate buffer prepared as follows. Dissolve 6.805 g of monobasic potassium phosphate and 0.896 g of sodium hydroxide in and dilute with water to 1000 mL. Adjust with 0.2 M sodium hydroxide or 1 M… Read More
RISPERIDONE ADDITIONAL REQUIREMENTS/USP Reference Standards <11> Second Supplement to USP37–NF32 7240 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 2 of USP Risperidone Related Compound G RS: Change
3-[2-[4-(4-Fluoro-2-hydroxybenzoyl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one.
C23H28FN3O3 413.49
to:
3-[2-[4-(4-… Read More
CAFFEINE CITRATE INJECTION ASSAY/Procedure USP38–NF33 2520 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 5 of Analysis: Change
Result = (rU/rS) × CS × (Mr1/Mr2) × 100
to:
Result = (rU/rS) × C Read More
GANODERMA LUCIDUM FRUITING BODY POWDER COMPOSITION/Content of Triterpenoic Acids Revision Bulletin (Official August 01, 2014) Online 1-Dec-2014 USP39–NF34 Second Supplement to USP38–NF33 Line 1 of Standard solution A: Change
USP Ganoderic Acid RS
to:
USP Ganoderic Acid A RS
AND
Line 3 of variable definition list in Analysis: Change
rS = peak area of ganoderic acid in Standard solution A
to:
rS… Read More
CEFUROXIME AXETIL FOR ORAL SUSPENSION ASSAY/Procedure USP37–NF32 2243 1-Dec-2014 USP39–NF34 Second Supplement to USP38–NF33 Change
Buffer: 23 mg/mL of monobasic ammonium phosphate in water
to:
Solution A: 23 g/L of monobasic ammonium phosphate in water
AND
Line 4 of System suitability solution: Change
Dilute with Buffer to volume.
to:
Dilute with Solution A to… Read More
MANNITOL INJECTION Assay USP37–NF32 3653 1-Dec-2014 USP39–NF34 Second Supplement to USP38–NF33 Change:
Mobile phase, Resolution solution, and Chromatographic system—Proceed as directed in the Assay under Mannitol.
to:
Mobile phase—Use degassed water.
Resolution solution—Dissolve sorbitol and USP Mannitol RS in water to obtain a… Read More
SACCHARIN SODIUM IDENTIFICATION/B. Procedure USP37–NF32 4638 1-Dec-2014 USP39–NF34 Second Supplement to USP38–NF33 Line 1 of Analysis: Change
To the Sample solution
to:
To 10 mL of the Sample solution
ZANAMIVIR ASSAY/Procedure/Chromatographic system USP37–NF32 5197 1-Dec-2014 USP39–NF34 Second Supplement to USP38–NF33 Line 1 of Column: Change
5-μm packing L##1
to:
5-μm packing L82
AND
Delete footnote 1
COPOVIDONE IMPURITIES/Limit of Monomers (1-Vinyl-2-Pyrrolidone, Vinyl Acetate, and 2-Pyrrolidone) USP37–NF32 5938 1-Dec-2014 USP39–NF34 Second Supplement to USP38–NF33 Line 29 of Analysis: Change
Calculate the content of 2-pyrrolidinone
to:
Calculate the content of 2-pyrrolidone
GLYCERYL BEHENATE DEFINITION Second Supplement to USP37–NF32 7077 1-Dec-2014 USP39–NF34 Second Supplement to USP38–NF33 Line 7: Change
behenic (docosanic) acid
to:
behenic (docosanoic) acid
GANODERMA LUCIDUM FRUITING BODY COMPOSITION/Content of Triterpenoic Acids Revision Bulletin (Official August 01, 2014) Online 1-Dec-2014 USP39–NF34 Second Supplement to USP38–NF33 Line 1 of Standard solution A: Change
USP Ganoderic Acid RS
to:
USP Ganoderic Acid A RS
AND
Line 3 of variable definition list in Analysis: Change
rS = peak area of ganoderic acid in Standard solution A
to:
rS… Read More
<1788> METHODS FOR THE DETERMINATION OF PARTICULATE MATTER IN INJECTIONS AND OPHTHALMIC SOLUTIONS LIGHT OBSCURATION PARTICLE COUNT TEST/Instrument Standardization Tests/Particle Counting Accuracy—System Suitability USP37–NF32 1301 1-Dec-2014 USP39–NF34 Second Supplement to USP38–NF33 Line 11 of Method 2—Multichannel Instruments: Change
NMT ±10% of stated size.
to:
NMT ±10% of stated concentration.
FLUTAMIDE ASSAY/Procedure USP37–NF32 3057 1-Dec-2014 USP39–NF34 Second Supplement to USP38–NF33 Line 2 of Sample solution: Change
Dissolve the sample in acetonitrile
to:
Dissolve a previously dried sample in acetonitrile